Skip to main content
. Author manuscript; available in PMC: 2022 Feb 24.
Published in final edited form as: Cell Rep. 2021 Dec 14;37(11):110096. doi: 10.1016/j.celrep.2021.110096

Figure 6. Validation of identified EGFR inhibitor-sensitive RAS mutants in additional model systems.

Figure 6.

(A) Table of additional RAS mutant CRC cell lines that were investigated for EGFR inhibitor sensitivity.

(B) Drug dose-response assays for the additional cell lines. Data points and error bars represent the mean ± SD (n = 8).

(C) RBD-IEF after cetuximab treatment for theadditional cell lines.

(D) Quantification of RAS-GTP levels from RBD-IEF. Data points and error bars represent the mean ± SD from three separate experiments. Statistical significance was determined by unpaired two-tailed t est between untreated and treated conditions. *p < 0.05.

(B) and (C) are each representative of three independent experiments. CTX, cetuximab; NA, not applicable; Ctrl, control; WCL, whole cell lysate, PI, isoelectric point.